Solaris Resources Inc.
No enriched coverage for $SLSR in the last 7 days.
No SEC Form 4 filings for $SLSR in the last 30 days.
See all $SLSR insider activity →Red Cat (RCAT) analysts predict 115% upside to $18 per share despite rising expenses. Taysha (TSHA) advances TSHA-102 for Rett syndrome, awaiting FDA application. Solaris (SLSR) eyes 118% gain if Warintza copper project succeeds, pending feasibility study.
Simply Wall St reports Solaris Resources (TSX:SLS) posted Q2 2026 net loss of US$3.49M and basic loss per share of US$0.02, versus US$0.03 a year earlier. H1 2026 net loss was US$8.45M, basic and diluted loss per share US$0.05. Shares were CA$11.17 on 6 Aug 2026; analysts’ consensus price target is CA$21.30.
Recent SLSR coverage spans financial news and earnings.
Feasibility outcome could materially affect valuation.
Simply Wall St reports Solaris Resources (TSX:SLS) posted Q2 2026 net loss of US$3.49M and basic loss per share of US$0.02, versus US$0.03 a year earlier. H1 2026 net loss was US$8.45M, basic and diluted loss per share US$0.05. Shares were CA$11.17 on 6 Aug 2026; analysts’ consensus price target is CA$21.30.
AlphAI scores every news story that mentions SLSR with an AI model for sentiment and relevance, and aggregates insider trades from Solaris Resources Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Red Cat (RCAT) analysts predict 115% upside to $18 per share despite rising expenses. Taysha (TSHA) advances TSHA-102 for Rett syndrome, awaiting FDA application. Solaris (SLSR) eyes 118% gain if Warintza copper project succeeds, pending feasibility study.
2 min readSimply Wall St reports Solaris Resources (TSX:SLS) posted Q2 2026 net loss of US$3.49M and basic loss per share of US$0.02, versus US$0.03 a year earlier. H1 2026 net loss was US$8.45M, basic and diluted loss per share US$0.05. Shares were CA$11.17 on 6 Aug 2026; analysts’ consensus price target is CA$21.30.
6 min read
